Impel Neuropharma recently showed that their “nose-to-brain drug delivery device” could successfully deliver peptides to human brains – completely bypassing the blood-brain barrier. This trial was one of the first of its kind in humans showing that drugs administered through the nose are able to reach the exposed primary neurons located in the upper nasal passage. This advance is an important first step towards targeted delivery of drugs to the brain, which in some cases may help minimize side effects that come from taking the drug orally. Impel Neuropharma is confident that they can delivery larger proteins using their device (maybe those SOD1 antibodies you just read about?). Click on the link below to read the full story.
Click here to read more.Share this: